CapsoVision Revenue Jumps 17 Percent

CapsoVision (NASDAQ:CV), a medical technology company focused on capsule endoscopy systems, released its second quarter 2025 results on August 14, 2025. The company posted a 17% rise in revenue (GAAP) to $3.3 million, slightly beating analyst expectations, as revenue (GAAP) of $3.3 million exceeded the analyst estimate of $3.25 million. However, the reported loss per share (GAAP) was $2.02, much worse than the anticipated $0.11 GAAP loss. Cash reserves were $1.1 million, but a $23.4 million initial public offering in July 2025 significantly improved liquidity. The period showed revenue traction and strong customer growth, though continued high costs and operating losses remain significant hurdles. Source: Analyst estimates for the quarter provided by FactSet. CapsoVision develops and markets advanced capsule endoscopy systems. Its main products, CapsoCam Plus and the pipeline CapsoCam Colon, are swallowable cameras that capture images of the digestive tract to help diagnose intestinal conditions. These systems offer a minimally invasive solution compared to traditional endoscopy procedures.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool